Background Nanoliposomal irinotecan (Nal-IRI) is a preferred second-line treatment for metastatic pancreas cancer. It is unclear, however, whether patients who had received irinotecan derive benefit. Methods Medical records of metastatic pancreas cancer patients who had received irinotecan and then Nal...
In the pivotal phase 3 NAPOLI 3 trial (NCT04083235), the combination of irinotecan liposome injection (Onivyde), 5-fluorouracil (5-FU), oxaliplatin, and leucovorin (NALIRIFOX) improved overall survival (OS) and progression-free survival (PFS) compared with nab-paclitaxel plus gemcitabine in pr...
IrinotecanSurvivalBackground: Nanoliposomal irinotecan (Nal-IRI) is a preferred second-line treatment for metastatic pancreas cancer. It is unclear, however, whether patients who had received irinotecan derive benefit.Pancreatology: official journal of the International Association of Pancreatology (IAP) ....
P-287Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): a randomized, open-label phase 2 studydoi:10.1093/annonc/mdw199.277Dean Andrew...
Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer. Expert Opin. Pharmacother. 17(10), 1413-1420 (2016).Chiang, Nai-Jung,Chen,etc.Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic...
O-004Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trialdoi:10.1093/annonc/mdy149.003Mercadé T MacarullaLee KLakatos GWang-Gillam A...
FitzgeraldDavid AJaffrayEJNMMI researchZheng J, Klinz SG, De Souza R, et al. Longitudinal tumor hypoxia imaging with [(18)F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity. EJNMMI Res. 2015; 5: 57....
In an effort to reduce toxicities and optimize outcomes, this investigation explores the safety and feasibility of substituting liposomal irinotecan (nal-IRI) for nonliposomal irinotecan to improve tumor drug delivery and potentially reduce toxicity. This regimen, NALIRIFOX, has the potential to be ...
A phase 1/2 study (Wainberg et al. Eur J Cancer 2021;151:14–24; NCT02551991) demonstrated promising anti-tumor activity in patients with mPDAC who received first-line liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2 (NALIRIFOX). Herein, we...
Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 studydoi:10.1093/annonc/mdy432.051L.-T. Chen...